Land: Australien
Sprache: Englisch
Quelle: Department of Health (Therapeutic Goods Administration)
Pertussis filamentous haemagglutinin; Pertussis toxoid; Diphtheria toxoid; Tetanus toxoid; Pertactin
GlaxoSmithKline Australia Pty Ltd
Medicine Registered
1 BOOSTRIX _Combined Diphtheria-Tetanus-acellular Pertussis (dTpa) Vaccine _ CONSUMER MEDICINE INFORMATION LEAFLET WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about BOOSTRIX vaccine. It does not contain all the available information. It does not take the place of talking to your doctor, nurse or pharmacist. All medicines and vaccines have risks and benefits. Your doctor has weighed the possible risks of having BOOSTRIX against the expected benefits. IF YOU HAVE ANY CONCERNS ABOUT RECEIVING BOOSTRIX TALK TO YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET WITH THIS VACCINE. You may need to read it again WHAT BOOSTRIX IS USED FOR BOOSTRIX is a vaccine used as a booster to prevent three diseases: diphtheria, tetanus and pertussis (whooping cough) in adults and children aged 10 years and older who have been previously vaccinated against these diseases. The vaccine works by causing the body to produce its own protection (antibodies) against these diseases. Diphtheria, tetanus, and pertussis are all serious life- threatening diseases caused by bacterial infection. DIPHTHERIA Diphtheria mainly affects the airways and sometimes the skin. Generally the airways become inflamed (swollen) causing severe breathing difficulties and sometimes suffocation. The bacteria also release a toxin (poison), which can cause nerve damage, heart problems, and death. The risk of serious complications and death is greater in the very young and elderly. TETANUS (Lockjaw) Tetanus bacteria enter the body through wounded skin. Wounds that are especially prone to infection are burns, fractures, deep wounds or wounds contaminated with soil, dust, horse manure or wood splinters. The bacteria release a toxin (poison), which can c Lesen Sie das vollständige Dokument
1 BOOSTRIX PRODUCT INFORMATION Combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine DESCRIPTION BOOSTRIX dTpa vaccine is a sterile suspension which contains diphtheria toxoid, tetanus toxoid and three purified antigens of _Bordetella pertussis _[pertussis toxoid (PT), pertussis filamentous haemagglutinin (FHA) and pertactin (PRN)] adsorbed onto aluminium salts. BOOSTRIX is a turbid white suspension for injection._ _ 1 dose (0.5 ml) contains: Diphtheria toxoid 1 not less than 2 International Units (IU) (2.5 Lf) Tetanus toxoid 1 not less than 20 International Units (IU) (5 Lf) Bordetella pertussis antigens Pertussis toxoid 1 8 micrograms Filamentous Haemagglutinin 1 8 micrograms Pertactin 1 2.5 micrograms 1 adsorbed on aluminium hydroxide, hydrated (Al(OH) 3 ) 0.3 milligrams Al 3+ and aluminium phosphate (AlPO 4 ) 0.2 milligrams Al 3+ The diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine (dTpa) components are adsorbed on 0.5mg aluminium in the form of aluminium hydroxide and aluminium phosphate, and suspended in isotonic sodium chloride. The vaccine preparation also contains phenoxyethanol as a preservative and formaldehyde, polysorbate 80 and glycine in residual amounts. The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. No substances of human origin are used in its manufacture. 2 CLINICAL PHARMACOLOGY BOOSTRIX (dTpa vaccine) induces antibodies against all vaccine components. CLINICAL TRIALS Immune response results to the diphtheria, tetanus and acellular pertussis components in four comparative studies (dTpa vers Lesen Sie das vollständige Dokument